Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
713 (USA) · Dr. Kowalski
consented 2014-01-19
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-03-19 (study day 60.0); relationship: PROBABLE
moderate
assessed
Moderate APPLICATION SITE IRRITATION — outcome: RECOVERED/RESOLVED; onset 2014-03-19 (study day 60.0); relationship: PROBABLE
mild
assessed
Mild NAUSEA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-03-27 (study day 68.0); relationship: POSSIBLE
mild
assessed
Mild NAUSEA — outcome: RECOVERED/RESOLVED; onset 2014-03-27 (study day 68.0); relationship: POSSIBLE
Data queries
No data queries.